Darovasertib

DRUG4 trials

Sponsors

St Vincent's Hospital, Sydney, IDEAYA Biosciences

Conditions

Ocular MelanomaUveal Melanoma

Phase 2

Neoadjuvant/Adjuvant Trial of Darovasertib in Ocular Melanoma

CompletedNCT05187884

St Vincent's Hospital, SydneyOcular Melanoma

Start: 2022-05-03End: 2025-11-01Updated: 2026-04-23

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Active, not recruitingNCT05907954

IDEAYA BiosciencesUveal Melanoma

Start: 2023-07-03End: 2030-04-30Target: 160Updated: 2026-03-16

Phase 3

Neoadjuvant Darovasertib in Primary Uveal Melanoma

RecruitingNCT07015190

IDEAYA BiosciencesUveal Melanoma

Start: 2026-01-25End: 2031-03-01Target: 520Updated: 2026-05-06

Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

RecruitingNCT07804186

IDEAYA BiosciencesUveal Melanoma

Start: 2026-09-01End: 2034-04-01Target: 450Updated: 2026-09-15

Related Papers

Neoadjuvant darovasertib in uveal melanoma patients undergoing primary local therapy (OptimUM-10): Phase 3 trial.

Journal of Clinical Oncology2026-05-28

A phase 2 safety and efficacy study of neoadjuvant/adjuvant darovasertib for localized ocular melanoma.

Journal of Clinical Oncology2024-06-015 citations

NADOM trial: Neoadjuvant/adjuvant trial of darovasertib in ocular melanoma (OM).

Journal of Clinical Oncology2023-06-015 citations